Publications
- Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer2018 | First Faculty of Medicine, Second Faculty of Medicine
- Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice2017 | Second Faculty of Medicine
- Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death2017 | Second Faculty of Medicine
- Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy2016 | Second Faculty of Medicine
- High hydrostatic pressure induces immunogenic cell death in human tumor cells2014 | Second Faculty of Medicine
- Consensus guidelines for the detection of immunogenic cell death2014 | Second Faculty of Medicine
- Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy2013 | Second Faculty of Medicine
- FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer2009 | First Faculty of Medicine, Faculty of Physical Education and Sport, Second Faculty of Medicine
- Imunogenic cell death and it ´s application in immunotherapy protocolsPublication without faculty affiliation
- Type I interferon and cancer2024 | Second Faculty of Medicine
Loading network view...